Head-to-head evidence
Adipose-derived MSC clusters (S.Biomedics) vs ALF201
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: No discrete molecular target · full Atherosclerotic Cardiovascular Disease pipeline
Adipose-derived MSC clusters (S.Biomedics)
Developed by S.Biomedics
NCT04661644 · Phase 1/2 · completed
The study was nonrandomized, open-label, and had no placebo or standard-treatment control arm; it enrolled 20 participants across sequential dose groups. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
ALF201
Developed by Allife Medical Science and Technology
NCT06359912 · Phase 1 · status unknown
This is a randomized study with a standard-of-care control group, but it is not blinded, enrolls a small number of patients, and its primary focus is safety rather than a disease-specific efficacy outcome; no results have been posted yet.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Adipose-derived MSC clusters (S.Biomedics)'s landscape · ALF201's landscape